U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06868043) titled 'A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days' on March 04.
Brief Summary: Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2). Duration up to 11 weeks: up to 6 weeks of screening phase (42 days); 4 weeks of treatment/measurement phase (28 days, depending on sensor functionality) and 1 week of follow up (7 days)
Study Start Date: July, 2012
Study Type: INTERVENTIONAL
Condition:
Diabetes (DM)
Intervention:
DEVICE: FiberSense System...